Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

T-Cell Redirecting Bispecific Antibodies Report 2016 - Analysis, Technologies & Forecasts - Key Vendors: Adimab, Affimed Therapeutics, Alligator Biosciences - Research and Markets

Research and Markets
Posted on: 01 Sep 16

Research and Markets has announced the addition of the "T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals" report to their offering.

Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields of cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR).

Despite stunning clinical results with CD19-targeted CAR T-cells, many major pharmaceutical companies have not embarked on this field of adoptive cell therapy, probably because cell products are a world completely different from that of small molecules or recombinant proteins and antibodies.

Tremendous progress in bispecific antibody technologies during the last decade and the clinical success of a first generation bispecific T-cell engager (BiTE) antibody molecule directed against CD19 lead to an explosion of T-cell redirecting bispecific antibodies in clinical development.

What will you find in the report?

  • Profiles of 34 companies active in the field
  • Comprehensive description of 23 established and emerging T-cell or NK-cell redirecting antibodies
  • Profiles of two approved and 45 T-cell or NK-cell redirecting bispecific antibodies in all phases of development
  • Key characteristics of technologies with clinical stage drug candidates
  • Emerging alternative bi- and trispecific formats
  • Target selection and competition in drug candidates
  • Competition of recombinant bispecific molecules with alternative treatment modalities

Companies Mentioned Include:

  • Adimab
  • Affimed Therapeutics
  • Alligator Biosciences
  • Ambrx
  • Amgen
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • CytomX
  • Eli Lilly
  • Emergent BioSolutions
  • EngMab
  • Eureka Therapeutics
  • GEMoaB
  • Generon
  • Genmab
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Pfizer
  • Pieris Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Roche
  • Servier
  • Wuhan YZY Biopharma
  • Xencor
  • Zymeworks

Report Structure:

1. Introduction

2. Executive Summary

3. Competitive Landscape Analysis

4. Company Profiles

5. Technology Profiles

6. Drug & Drug Candidate Profiles

7. References

8. Attachment

For more information about this report visit

View source version on

Business Wire

Last updated on: 01/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.